MNPR - Monopar Therapeutics Inc. Common Stock

Day	1m	10m	60m	PreMarket	Market	AfterHours	Gap
96.4 -6.07 (-6.3%)	---	---	---	---	-6.07 (-6.3%)	---	---

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.

Category: PHARMACEUTICAL PREPARATIONS

Market Period: Closed

Earnings & Ratios

Basic EPS:: -0.35
Diluted EPS:
Basic P/E:: -258.0857
Diluted P/E:
RSI(14) 1m:: 0.0
VWAP:: 90.46
RVol:: 0.5157

Events

Period	Kind	Movement	Occurred At
1m	Price increase 1m	91.9 +0.91 (+1.0%)	Oct 15 14:38
10m	Price increase 10m	91.9 +2.78 (+3.12%)	Oct 15 14:38
1m	Price decrease 1m	93.0 -1.09 (-1.16%)	Oct 15 11:32
1m	Price decrease 1m	96.23 -1.11 (-1.14%)	Oct 15 10:17
1m	Price increase 1m	98.91 +2.82 (+2.93%)	Oct 15 09:38